Targeting DDX17: A Promising Strategy for treating Cancer and Neurodegenerative Diseases

Target Name: DDX17

NCBI ID: G10521

DDX17

Targeting DDX17: A Promising Strategy for treating Cancer and Neurodegenerative Diseases

The development of new pharmaceuticals is a critical aspect of modern medicine. One of the most promising strategies in the fight against disease is the use of target-based therapeutics, which involve identifying specific proteins or biomarkers that are associated with a particular disease and then targeting them with drugs to treat the disease. One of the most promising protein targets in recent years is the protein known as DDX17, which is associated with a number of diseases including cancer, neurodegenerative diseases, and autoimmune disorders. In this article, we will explore the biology of DDX17, its potential as a drug target, and the current state of research in this field.

The biology of DDX17

DDX17 is a protein that is expressed in a wide range of tissues throughout the body, including the brain, muscle, heart, and blood vessels. It is a member of the microtubule-associated protein (MAP) family, which is known for their role in the transport of organelles within cells. MAP proteins play a critical role in the proper functioning of cells, and alterations in their levels or function can be associated with a number of diseases.

One of the most significant functions of DDX17 is its role in the development and maintenance of cancer. Cancer is a complex disease that is characterized by the uncontrolled growth and proliferation of cells. The development of cancer is often associated with the breakdown of normal cellular processes , and disruptions in the MAP protein family can play a critical role in this process. For example, studies have shown that DDX17 is highly expressed in a variety of cancer types, including breast, ovarian, and colorectal cancers. Additionally, altered levels of DDX17 have has been observed in a number of cancer-associated tissues, such as the bloodstream and lymphatic system.

DDX17 is also involved in the development and progression of neurodegenerative diseases. Neurodegenerative diseases are a group of conditions that are characterized by the progressive loss of brain cells and the development of progressive neuropsychiatric symptoms. Again, the MAP protein family plays a critical role in the development of these diseases. Studies have shown that DDX17 is highly expressed in the brain and that it is involved in the development of a number of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.

DDX17 is also involved in the immune system and has been implicated in a number of autoimmune disorders. Autoimmune disorders are a group of conditions that are characterized by the immune system attacking the body's own tissues. Again, the MAP protein family plays a critical role in the development of these disorders. Studies have shown that DDX17 is highly expressed in a variety of autoimmune tissues, including the gut and the skin. Additionally, altered levels of DDX17 have been observed in a number of autoimmune disorders, including rheumatoid arthritis and multiple sclerosis.

Potential as a drug target

The potential of DDX17 as a drug target is due to its involvement in a wide range of diseases. Its involvement in cancer, neurodegenerative diseases, and autoimmune disorders makes it an attractive target for drug development. Additionally, its role in the MAP protein family makes it possible that drugs that target other MAP proteins may also be effective in treating these diseases.

One of the most promising strategies for targeting DDX17 is the use of small molecules. Small molecules are drugs that are derived from natural sources and are often used to treat a wide range of diseases. The use of small molecules as

Protein Name: DEAD-box Helicase 17

Functions: As an RNA helicase, unwinds RNA and alters RNA structures through ATP binding and hydrolysis. Involved in multiple cellular processes, including pre-mRNA splicing, alternative splicing, ribosomal RNA processing and miRNA processing, as well as transcription regulation. Regulates the alternative splicing of exons exhibiting specific features (PubMed:12138182, PubMed:23022728, PubMed:24910439, PubMed:22266867). For instance, promotes the inclusion of AC-rich alternative exons in CD44 transcripts (PubMed:12138182). This function requires the RNA helicase activity (PubMed:12138182, PubMed:23022728, PubMed:24910439, PubMed:22266867). Affects NFAT5 and histone macro-H2A.1/MACROH2A1 alternative splicing in a CDK9-dependent manner (PubMed:26209609, PubMed:22266867). In NFAT5, promotes the introduction of alternative exon 4, which contains 2 stop codons and may target NFAT5 exon 4-containing transcripts to nonsense-mediated mRNA decay, leading to the down-regulation of NFAT5 protein (PubMed:22266867). Affects splicing of mediators of steroid hormone signaling pathway, including kinases that phosphorylates ESR1, such as CDK2, MAPK1 and GSK3B, and transcriptional regulators, such as CREBBP, MED1, NCOR1 and NCOR2. By affecting GSK3B splicing, participates in ESR1 and AR stabilization (PubMed:24275493). In myoblasts and epithelial cells, cooperates with HNRNPH1 to control the splicing of specific subsets of exons (PubMed:24910439). In addition to binding mature mRNAs, also interacts with certain pri-microRNAs, including MIR663/miR-663a, MIR99B/miR-99b, and MIR6087/miR-6087 (PubMed:25126784). Binds pri-microRNAs on the 3' segment flanking the stem loop via the 5'-[ACG]CAUC[ACU]-3' consensus sequence (PubMed:24581491). Required for the production of subsets of microRNAs, including MIR21 and MIR125B1 (PubMed:24581491, PubMed:27478153). May be involved not only in microRNA primary transcript processing, but also stabilization (By similarity). Participates in MYC down-regulation at high cell density through the production of MYC-targeting microRNAs (PubMed:24581491). Along with DDX5, may be involved in the processing of the 32S intermediate into the mature 28S ribosomal RNA (PubMed:17485482). Promoter-specific transcription regulator, functioning as a coactivator or corepressor depending on the context of the promoter and the transcriptional complex in which it exists (PubMed:15298701). Enhances NFAT5 transcriptional activity (PubMed:22266867). Synergizes with TP53 in the activation of the MDM2 promoter; this activity requires acetylation on lysine residues (PubMed:17226766, PubMed:20663877, PubMed:19995069). May also coactivate MDM2 transcription through a TP53-independent pathway (PubMed:17226766). Coactivates MMP7 transcription (PubMed:17226766). Along with CTNNB1, coactivates MYC, JUN, FOSL1 and cyclin D1/CCND1 transcription (PubMed:17699760). Alone or in combination with DDX5 and/or SRA1 non-coding RNA, plays a critical role in promoting the assembly of proteins required for the formation of the transcription initiation complex and chromatin remodeling leading to coactivation of MYOD1-dependent transcription. This helicase-independent activity is required for skeletal muscle cells to properly differentiate into myotubes (PubMed:17011493, PubMed:24910439). During epithelial-to-mesenchymal transition, coregulates SMAD-dependent transcriptional activity, directly controlling key effectors of differentiation, including miRNAs which in turn directly repress its expression (PubMed:24910439). Plays a role in estrogen and testosterone signaling pathway at several levels. Mediates the use of alternative promoters in estrogen-responsive genes and regulates transcription and splicing of a large number of steroid hormone target genes (PubMed:24275493, PubMed:20406972, PubMed:20663877, PubMed:19995069). Contrary to splicing regulation activity, transcriptional coregulation of the estrogen receptor ESR1 is helicase-independent (PubMed:19718048, PubMed:24275493). Plays a role in innate immunity. Specifically restricts bunyavirus infection, including Rift Valley fever virus (RVFV) or La Crosse virus (LACV), but not vesicular stomatitis virus (VSV), in an interferon- and DROSHA-independent manner (PubMed:25126784). Binds to RVFV RNA, likely via structured viral RNA elements (PubMed:25126784). Promotes mRNA degradation mediated by the antiviral zinc-finger protein ZC3HAV1, in an ATPase-dependent manner (PubMed:18334637)

The "DDX17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DDX17 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets